CareMore, STSI and Sentrian launch COPD clinical trial

Sentrian

Sentrian has teamed-up with the Scripps Translational Science Institute (STSI) to study the effect of Sentrian’s Remote Patient Intelligence (RPI) platform on 1,000 patients with chronic obstructive pulmonary disease (COPD).┬áThe patients are all health plan members of CareMore Health System, a wholly owned subsidiary of Anthem.

The adaptive research study’s objective is to determine whether Sentrian’s technology can detect patient deterioration in advance of an acute event and with high accuracy, helping to reduce avoidable hospital admissions and readmissions for COPD patients while lowering their cost of care. Nationally, one in 11 patients with COPD are readmitted to a hospital within 30 days of discharge.

In the US, one in 11 patients with COPD are readmitted to a hospital within 30 days of discharge.“This research collaboration with Sentrian and CareMore fits nicely with our mission at Scripps to study the latest advances in digital medicine technologies as part of our effort to replace traditional one-size-fits-all medicine with precision health care and to accelerate patient access to effective new approaches to treating illnesses,” said Dr. Steven Steinhubl, director of digital medicine at STSI.

Sentrian recently began providing an integrated remote patient monitoring and analytics service to 1,000 CareMore health plan members with COPD and other concomitant conditions. The patent-pending Sentrian RPI solution leverages remote biosensors and machine learning to remotely detect deterioration in patients’ health with enough advance warning to intervene before the event becomes acute and requires hospitalization.

With Scripps’ participation, the project will evolve into a formal 12-month research study. The findings could significantly reform disease management not only for COPD, but for other chronic diseases, which account for 75 percent of U.S. health care costs.